© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
*CDCA is not indicated for CTX, but has received a medical necessity determination in the US by the FDA for CTX. Travere Therapeutics is conducting a Phase 3 clinical trial to examine the safety and efficacy of CDCA (Chenodal®) for the treatment of CTX. **Pegtibatinase (TVT-058) is currently in a Phase 1/2 clinical study.
FSGS: focal segmental glomerulosclerosis; IgAN: IgA nephropathy; CTX: cerebrotendinous xanthomatosis; HCU: classical homocystinuria; NGLY1 deficiency: N-glycanase 1 deficiency; ALGS: Alagille syndrome
We are involved in numerous clinical trials for our pipeline product candidates targeting rare chronic conditions. Find out which ones are enrolling and visit our clinical trial websites.
COMPASSIONATE USE REQUESTS
Do you, a loved one, or a patient have a critical need for immediate care outside of a clinical trial? Read about access to our investigational therapies.